Support program to help with regular eye injections
Part of Eyes & vision clinical trials.
This study tests whether a structured support program helps people stick to their regular eye injection schedule. It aims to improve treatment adherence for chronic eye conditions that require ongoing injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a chronic eye condition, such as wet age-related macular degeneration (AMD) or diabetic macular edema (DME).
- You are either starting eye injections for the first time or have had injections in the past 6 months and need another one now.
- You are a Singapore resident.
- You speak English or Mandarin fluently.
- You are able to give informed consent and are willing to participate in the study's multidisciplinary program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially trained nurses can safely give eye injections instead of doctors. It may make treatment quicker and easier for people who need regular injections for eye conditions.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This trial tests a more frequent dosing of an eye injection called pegaptanib (Macugen) to see if it can quickly reduce swelling in the retina caused by diabetes and improve vision. It is for people with diabetic macular edema who have some vision loss.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.